Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inspire Medical Systems (INSP) EBITDA Margin (2017 - 2025)

Inspire Medical Systems (INSP) has disclosed EBITDA Margin for 9 consecutive years, with 50.51% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 3630.0% to 50.51% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 15.94% through Dec 2025, up 931.0% year-over-year, with the annual reading at 15.94% for FY2025, 931.0% up from the prior year.
  • EBITDA Margin hit 50.51% in Q4 2025 for Inspire Medical Systems, up from 4.53% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 50.51% in Q4 2025 to a low of 40.24% in Q1 2021.
  • Historically, EBITDA Margin has averaged 3.9% across 5 years, with a median of 4.36% in 2021.
  • Biggest five-year swings in EBITDA Margin: surged 16592bps in 2021 and later crashed -645bps in 2025.
  • Year by year, EBITDA Margin stood at 3.11% in 2021, then skyrocketed by 180bps to 2.49% in 2022, then surged by 224bps to 8.06% in 2023, then skyrocketed by 76bps to 14.21% in 2024, then surged by 256bps to 50.51% in 2025.
  • Business Quant data shows EBITDA Margin for INSP at 50.51% in Q4 2025, 4.53% in Q3 2025, and 1.58% in Q2 2025.